Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

The Nemours Foundation

Neither a doctor nor a teaching hospital

Research payments

$3,665,006

299 payments

Through program year 2025, The Nemours Foundation is reported as receiving $3,665,006 in research payments, across 299 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $317,517 35
2024 Research $311,373 57
2023 Research $360,022 88
2022 Research $1,319,346 24
2021 Research $521,388 30
2020 Research $451,098 22
2019 Research $384,261 43

Breakdown

Who paid Research payments · program years 2019–2025
  1. Biogen, Inc. $1,676,676 12 payments
  2. Novo Nordisk Inc $522,929 4 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $339,466 87 payments
  4. GlaxoSmithKline, LLC. $301,072 53 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $162,395 11 payments
  6. Pfizer Inc. $98,877 9 payments
  7. Sumitomo Pharma America, Inc. $96,752 11 payments
  8. Medtronic, Inc. $91,993 15 payments
  9. Aurinia Pharma U.S., Inc. $91,966 9 payments
  10. Ucb SA $49,620 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational Studies of ISIS 396443 $761,610 1 payment
  2. A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies. $539,775 3 payments
  3. rhGH: effects on metabolic profile, body composition, skeletal muscle strength and function $522,929 4 payments
  4. Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of A 12-Week Double-Blind, Placebo-Controlled Part (Part A) to Evaluate Efficacy and Safety Followed By A 36-Week Double-Blind Extension Part (Part B) to Document Long-Term Safety Up to Week 48 $243,996 67 payments
  5. An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy $196,137 1 payment
  6. A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $161,147 35 payments
  7. A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy $148,411 4 payments
  8. An Openlabel Expanded Access Protocol for Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options $127,641 15 payments
  9. 52 wks Eff. & Saf. Ph III in Paediatrics $102,452 17 payments
  10. A Randomised, Double-Blind, Parallel Group, Multicentre, Stratified, S $94,580 15 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record